|
 The company's shares jumped about 22 percent to
$3.35 in trading before the bell.
Enrolment for the study was halted after the death of a patient with
advanced breast cancer, who experienced acute liver failure about a
month after the drug, codenamed CUDC-427, was discontinued.
The trial began in the third quarter of 2013 in patients with
advanced solid tumors or lymphomas.
Curis said it planned to continue testing the drug — including in
combination with chemotherapy drug, capecitabine — in patients of a
type of advanced breast cancer.
The Lexington, Massachusetts-based company's shares closed at $2.75
on the Nasdaq on Friday.
(Reporting by Natalie Grover in Bangalore;
editing by Kirti Pandey)
[© 2014 Thomson Reuters. All rights
reserved.] Copyright 2014 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed. |
